Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brunangelo Falini

Showing results (191-200 of 246) with videos related to

Pageof 25
Sort By:
Blood|August 24, 2006
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classificationLaura Pasqualucci, Arcangelo Liso, Maria Paola Martelli, et al.
Haematologica|May 30, 2008
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco, Antonio Cuneo, Fabrizio Pane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2020
Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomasLucia Mundo, Leonardo Del Porro, Massimo Granai, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 3, 2020
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomasLucia Mundo, Leonardo Del Porro, Massimo Granai, et al.
Leukemia|November 7, 2020
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in micePaolo Sportoletti, Daniele Sorcini, Anna G Guzman, et al.
The Journal of Clinical Investigation|July 18, 2018
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fatesXiaorong Gu, Quteba Ebrahem, Reda Z Mahfouz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trialMaurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, et al.
Blood Advances|December 15, 2022
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AMLVincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, et al.
Pageof 25

Showing results (191-200 of 246) with videos related to

Sort By:
Pageof 25
Blood|August 24, 2006
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classificationLaura Pasqualucci, Arcangelo Liso, Maria Paola Martelli, et al.
Haematologica|May 30, 2008
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco, Antonio Cuneo, Fabrizio Pane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2020
Correction: Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomasLucia Mundo, Leonardo Del Porro, Massimo Granai, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 3, 2020
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomasLucia Mundo, Leonardo Del Porro, Massimo Granai, et al.
Leukemia|November 7, 2020
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in micePaolo Sportoletti, Daniele Sorcini, Anna G Guzman, et al.
The Journal of Clinical Investigation|July 18, 2018
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fatesXiaorong Gu, Quteba Ebrahem, Reda Z Mahfouz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trialMaurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, et al.
Blood Advances|December 15, 2022
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AMLVincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, et al.
Pageof 25